219 results about "Dendrite" patented technology

The invention relates to the technical field of new energy system fault diagnosis, in particular to a solar cell coupling hydrogen production system fault diagnosis method based on big data, and the method comprises the steps: collecting photovoltaic, electrolytic cell and control unit multi-source heterogeneous data, and detecting the abnormality through an abnormality detection core model; matching and repairing by combining historical similar sections to obtain operation re-repairing data; a multi-scale expansion convolutional neural network is adopted to extract time sequence fault features, a backbone network is adopted to extract infrared image high-order features, and heterogeneous aggregation features are obtained through fusion of a spiking neuron model and virtual dendritic branches; constructing dynamic graph nodes and attributes according to features and components, and integrating multiple indexes to fit a causal association strength weight; and multi-link diagnosis: obtaining a fault type through a quantum annealing algorithm, positioning a fault through causal discovery and a virtual dry prediction algorithm, integrating and reporting to a server. The method can improve the fault diagnosis accuracy and real-time performance, and is suitable for fault monitoring of the solar hydrogen production system.

The invention relates to the technical field of antitumor drugs, in particular to a Ru (II) complex and a preparation method and application thereof, and the Ru (II) complex has a structure as shown in a formula I. The Ru (II) complex synthesized by the method disclosed by the invention not only has relatively high cytotoxicity, but also has good photodynamic antitumor activity. After the complex is illuminated, the efficiency of the complex entering cells in an active transportation mode can be accelerated, mitochondria and endoplasmic reticulum are targeted at the same time, mitochondrial membrane potential decline and endoplasmic reticulum stress are caused to form a dual organelle damage effect, immunogenic cell death is caused, the tumor microenvironment is adjusted, and the tumor cell immunogenicity is improved. The enrichment of dendritic cells (DCs) in tumor cells is realized, the chemotactic activity of effector T cells is improved, the proportion of CD4 < + > and Foxp3 < + > cell populations is reduced, and finally the anti-tumor immune response is activated. Meanwhile, the complex provided by the invention can also induce the cell to generate pan apoptosis, retard the cell cycle in the G2 / M period and enhance the effect of the complex in inhibiting tumor proliferation.

The invention discloses a pulse neural network lightweight method based on nonlinear pruning, and relates to the technical field of artificial intelligence and neural networks. The method comprises the following steps: S1, constructing an NDI-LIF spiking neural network model, and introducing a bilinear product term into an input current in a dynamic updating process of a neuron membrane potential; s2, constructing a nonlinear synaptic pruning mechanism, representing a connection weight as a re-parameterization function composed of a re-parameterization weight and a conversion gain coefficient, and pruning the connection weight based on the re-parameterization function; and S3, training the NSPDI-SNN model to obtain a lightweight pulse neural network. By introducing a nonlinear dendritic integration mechanism and a state-adjustable synaptic pruning mechanism, balance between network sparsity and high performance is realized while the expression ability of the model is enhanced, and a lightweight spiking neural network model with high spatial-temporal expression ability, highly sparse structure and reasonable biological mechanism is constructed. And the generalization ability and the efficient training performance under various tasks are ensured.

Embodiments described herein relate to electrochemical cells with dendrite prevention mechanisms. In some aspects, an electrochemical cell can include an anode disposed on an anode current collector, a cathode disposed on a cathode current collector, the cathode having a first thickness at a proximal end of the cathode and a second thickness at a distal end of the cathode, the second thickness greater than the first thickness, a first separator disposed on the anode, a second separator disposed on the cathode, an interlayer disposed between the first separator and the second separator, the interlayer including electroactive material and having a proximal end and a distal end, and a power source electrically connected to the proximal end of the cathode and the proximal end of the interlayer, the power source configured to maintain a voltage difference between the cathode and the interlayer below a threshold value.

The invention relates to the technical field of brain science image processing, and discloses a brain tissue neuronal morphology three-dimensional reconstruction and connection group analysis method and system, and the method comprises the steps: carrying out the feature point extraction and matching and optical flow registration of continuous ultrathin section electron microscope images, and obtaining three-dimensional image volume data; carrying out semantic segmentation on cell bodies, dendrites, axons and dendritic spines through a three-dimensional deep convolutional neural network, and driving secondary registration through confidence feedback; detecting synapses and classifying the synapses as excitatory or inhibitory types; executing topology perception skeletonized reconstruction and performing segmentation correction through topology anomaly feedback constraint; and constructing a synaptic connection matrix and executing graph theory analysis.

The invention discloses a polar diaphragm optimization method based on a high-fidelity electrochemical-phase field model, which comprises the following steps: constructing a high-fidelity electrochemical-phase field model considering a diaphragm substrate and a polar coating to describe the growth behavior of lithium dendrites in the electrodeposition process of a lithium battery; collecting physical property parameters of the diaphragm matrix and the polar coating, substituting the physical property parameters into the model, establishing a computational domain and performing grid division; carrying out numerical solution on the model by utilizing a finite difference method to obtain growth morphology data of the lithium dendrites on the surface of the anode; and performing quantitative characterization on dendritic crystal morphology uniformity based on the growth morphology data to obtain dendritic crystal indexes, adjusting diaphragm physical property parameters according to the indexes, and repeating simulation iteration to optimize the diaphragm structure. By introducing multi-phase field sequence parameters and comprehensively describing the influence of the diaphragm matrix and the polar coating on lithium ion transmission, electrochemical reaction and interface characteristics, the high-precision simulation and optimization of the polar diaphragm design are realized, and the growth of lithium dendrites can be effectively inhibited.

The invention discloses an aptamer-modified lipid nano delivery platform as well as a preparation method and application thereof, and belongs to the field of biomedicine. The platform is prepared by taking DPPC, DOTAP and cholesterol as basic lipid components, Ce6 as a sound-sensitive agent and Flt3L as an immune agonist, controlling the particle size through gradient extrusion, and coupling cholesterol with an EpCAM aptamer for surface modification. The method has the core advantages that active targeting enrichment of tumors is realized by virtue of the aptamer, tumor cell immunogen cell death (ICD) is induced in combination with a sonodynamic therapy (SDT), and damage-related molecular patterns (DAMPs) are released; meanwhile, Flt3L is released in a tumor microenvironment, collection and activation of type 1 classical dendritic cells (cDC1) are specifically promoted, an'endogenous cDC1 vaccine 'is constructed, and CD8 + T cell mediated anti-tumor immune response is enhanced. Experiments prove that the platform can significantly improve the cDC1 infiltration level of a tumor site, effectively inhibit the progress of prostate cancer (PCa), and provide a new normal form for immune'cold tumor 'treatment.

Embodiments described herein relate to electrochemical cells with dendrite prevention mechanisms. In some aspects, an electrochemical cell can include an anode disposed on an anode current collector, a cathode disposed on a cathode current collector, the cathode having a first thickness at a proximal end of the cathode and a second thickness at a distal end of the cathode, the second thickness greater than the first thickness, a first separator disposed on the anode, a second separator disposed on the cathode, an interlayer disposed between the first separator and the second separator, the interlayer including electroactive material and having a proximal end and a distal end, and a power source electrically connected to the proximal end of the cathode and the proximal end of the interlayer, the power source configured to maintain a voltage difference between the cathode and the interlayer below a threshold value.

The invention discloses a novel immunologic adjuvant, a composition containing the immunologic adjuvant and a pharmaceutical composition. The immunologic adjuvant is picrasidine S. The immunologic adjuvant composition comprises picrasidine S and optionally one or more other types of immunologic adjuvants, such as an aluminum adjuvant. The pharmaceutical composition comprises an antigen and the immunologic adjuvant composition. Experiments prove that the picrasidine S can effectively stimulate dendritic cells to generate cell factors IFN-beta and IL-6, and has PS dose dependence; picrasidine S plays an important role in enhancing specific humoral immune response of different types of antigens, and has a stronger effect than an aluminum adjuvant; the picrasidine S immunity can enhance the anti-tumor immune response in different tumor models. According to the invention, a new candidate drug is provided for research and development of a new generation of vaccine adjuvants, and meanwhile, the medical application of the picrasidine S is also widened.

The invention provides a glioblastoma patient lifetime prediction method and system, and relates to the technical field of intelligent medical treatment, and the method comprises the steps: obtaining and coding a digital full-slice image of a patient; screening high-information-content image blocks based on information entropy; executing a dendritic calculation rule and a structural plasticity rule through internal learnable dendritic neurons by using a dendritic morphological neural calculation model, and extracting global and local features from the image blocks; fusing the features through feature fusion neurons to obtain depth features; and finally, predicting the total lifetime through the output neurons. By simulating hierarchical calculation and plasticity of neuron dendrites, a double-level feature learning model capable of integrating global context and local details of a full-slice image at the same time is constructed, and the technical problems that an existing prediction method is insufficient in feature integration and limited in model calculation structure are effectively solved. And more comprehensive and accurate prediction of the lifetime of the glioblastoma patient is realized.

This application relates to the field of tumor treatment technology, specifically to a drug combination and evaluation method for improving the sensitivity of MSS CRC to anti-PD-1 / PD-L1 therapy. The drug combination comprises vancomycin and an immune checkpoint inhibitor. Vancomycin is used to remodel the gut microbiota and reduce L-asparagine levels; the immune checkpoint inhibitor is used to activate CD8. + T-cell anti-tumor response. By combining vancomycin with immune checkpoint inhibitors, the antigen-presenting capacity of dendritic cells is enhanced, thereby increasing the sensitivity of MSS CRC to anti-PD-1 or anti-PD-L1 immunotherapy. This application focuses on the upstream initiation link of gut microbiota-metabolites-dendritic cells-immune activation, relieving the inhibition of dendritic cell antigen presentation by L-asparagine and enhancing CD8+. + T cell activation and tumor immune response enhance the sensitivity of MSS-type colorectal cancer to anti-PD-1 / PD-L1 therapy.

This invention relates to a self-adjuvanted biomimetic lipid nanoparticle, its microfluidic assembly method, and its anti-tumor applications. The self-adjuvanted biomimetic lipid nanoparticle has a structure in which an activated dendritic cell membrane (ADCM) is coated on the surface of a lipid nanoparticle (LNP) loaded with mRNA. The advancements of this invention compared to traditional LNPs are: the self-adjuvanted biomimetic lipid nanoparticle (ADCM-LNP) exhibits a faster cellular uptake rate and higher transfection efficiency, thereby inducing a strong Th1-type immune response and a potent CTL-mediated tumor-killing effect. In vivo biodistribution studies have shown that this system exhibits significant spleen-targeting (splenic tropism) and demonstrates excellent therapeutic efficacy in a HER2-positive breast cancer model.

The invention discloses application of pantothenic acid in regulating activation of dendritic cells and preparing an immunologic adjuvant. Experiments prove that the pantothenic acid has a remarkable promoting effect on related innate immunity and adaptive immunity of the dendritic cells; various vaccine models find that pantothenic acid can remarkably promote vaccine reactivity and is more efficient than traditional adjuvants, new application of pantothenic acid is provided, the application range of pantothenic acid is expanded, and the pantothenic acid has important economic benefits and social benefits.

A solid-state electrochemical cell includes a solid electrolyte where at least a portion of the electrolyte is in a compressive stress state. The compressive stress state includes at least one stress component that is orthogonal to the preferred direction of dendrite growth, which may correspond to the direction of an electric field. If the magnitude of the stress component is sufficiently large (e.g., greater than 50 MPa), then the growth of a dendrite passing through that portion of the electrolyte may be suppressed or deflected towards the direction of the applied stress component. In this manner, a dendrite may be deflected away from a cathode, thus prolonging the life of the cell. The compressive stress state may be generated by applying an external mechanical load to the cell and / or generating a residual stress in the cell during manufacture or assembly.

The present application relates to a dendritic cell-targeted allergen nanovaccine. The present application discloses a nanovaccine which is internally wrapped with an allergen and externally coupled with a dendritic cell targeting molecule. The present application also provides a preparation method and use of the nanovaccine. The nanovaccine can be specifically taken up by dendritic cells, and induce cell tolerance, and is used for specific immunotherapy of allergic diseases.

The present invention provides for chimeric antigen receptor constructs capable of being expressed in dendritic cells (DCs), and DCs modified to express one or more chimeric antigen receptors (CARs) as well as compositions comprising these modified DCs and methods of stimulating an adaptive immune response in a subject. The intracellular domain of the CAR comprises a toll-interleukin receptor (TIL) intracellular signalling domain and a costimulating domain selected from CD3 signalling domain, CD28 signalling domain and a combined CD28 and CD3 signalling domain.

Provided is a dendritic cell activator that contains, as an active ingredient, a component derived from a natural product which has been eaten for many years and the safety of which has been empirically confirmed, and that is used for inducing or promoting an acquired immune response effective against cancer or infectious disease. Specifically provided are: a dendritic cell activator containing, as an active ingredient, 5-(3,5-dihydroxyphenyl)-y-valerolactone represented by formula (I); and a medicine, a supplement, and a food or beverage each containing the compound represented by formula (I) as an active ingredient. [The configuration of the wavy line may be either R-form or S-form.]

The invention belongs to the technical field of biological medicines, and particularly discloses a pH and ultrasound double-response type oncolytic microorganism as well as a preparation method and application thereof. On the basis of a tumor targeting platform, a mild thermal response gene loop expression GM-CSF and a surface-coated oncolytic microbial system are integrated, chemotherapeutic drugs are released in a tumor core area, and immunogenic cell death is induced. A thermal response loop is accurately activated through low-intensity focused ultrasound, and engineering bacteria are promoted to express GM-CSF and secrete a large amount of mannose modified OMVs. Due to the nanometer size and mannose targeting of the OMVs, the OMVs are efficiently enriched in lymph nodes, the OMVs are reprogrammed into an immune activation state from an immune tolerance state, and the OMVs and ICD cooperate to promote dendritic cell maturation, tumor antigen presentation and activation of tumor killer T cells, so that a remarkable and powerful treatment effect is achieved in various tumor models, and the application prospect is wide. A new strategy is provided for remodeling the lymph node immune microenvironment and enhancing the anti-tumor immune response.

[Problem] To provide a method for producing a dendritic cell formulation that stimulates NKT cells, from monocytes collected from a recipient (monocytes collected by apheresis or peripheral blood containing monocytes), and that can exhibit the effect more quickly than conventional products. [Solution] This method for producing a dendritic cell formulation comprises: an adhesion step for placing collected monocytes in a culture vessel using a liquid culture medium, and leaving the culture vessel still to cause a portion of the monocytes to adhere to the inner surface of the vessel; a non-adhering cell removal step for removing non-adhering cells including monocytes other than the cells adhering to the inner surface of the culture vessel; a differentiation step for adding a predetermined factor in the culture vessel to cause the monocytes adhering to the inner surface of the culture vessel to differentiate into immature dendritic cells; a pulsing step for performing, with α-galactosylceramide, pulsing in the culture vessel in which the immature dendritic cells are present in a non-adhering state; and an NKT-stimulating dendritic cell induction step for inducing, from the immature dendritic cells, NKT-stimulating dendritic cells that stimulate NKT cells. The dendritic cell formulation is administered back into a recipient from which the blood have been collected.

The invention provides application of an arsenene nano preparation and / or beta-elemene in preparation of a product for treating brain tumors, and belongs to the technical field of biology. The arsenene nano preparation and / or beta-elemene are / is applied to brain glioma and lung cancer brain metastatic tumor model mice, so that tumor cells can be effectively killed, tumor metastasis can be inhibited, in-vivo immune response can be activated, maturation of dendritic cells can be promoted, NK cells and CD8 + T cells can be effectively activated, and the secretion amount of tumor suppression cell factors can be increased. Meanwhile, the beta-elemene effectively reduces cardiotoxicity caused by accumulation of the arsenene nano preparation in vivo.

The present disclosure relates to a composition for enhancing an immune response using the activating function of dendritic cells of a stromal vascular fraction isolated from adipose tissue, and in particular, a composition for enhancing an immune response for anti-tumor use.

The invention relates to the field of radiotherapy and, more particularly, to the use of a compound based on FMS-like tyrosine kinase 3 ligand (FLT3L) and adoptive cell therapy using dendritic cells in the prevention of cognitive damage associated with radiotherapy.

The invention discloses a culture medium composition for culturing dendritic cells and a culture method, and belongs to the field of biological medicines. Aiming at the problems of long induced differentiation period and low purity of the existing DC, the invention provides the culture medium composition for culturing the dendritic cells, the culture medium composition comprises a basic culture medium, an induction culture medium, a maturation culture medium and a function strengthening culture medium, the induction culture medium comprises the basic culture medium, and the maturation culture medium comprises a mature culture medium and a function strengthening culture medium; the GM-CSF, the IL-4, the astragalus polysaccharide and the rapamycin are added into the basic culture medium; the mature culture medium comprises a basic culture medium, and TNF-alpha, IFN-gamma, ganoderic acid and Poly (I: C) which are added into the basic culture medium, the function-enhanced culture medium comprises a basic culture medium, and IL-10, IL-12 and vitamin D3 which are added into the basic culture medium. The culture medium in each stage is combined with the synergistic effect of specific cell factors and natural plant extracts, so that high-purity and high-activity induction of the DC is realized, and the DC has the capability of resisting tumor microenvironment inhibition.

The invention discloses a multi-satellite multi-task constellation transmission decision-making method, which comprises the following steps: S1, splitting a plurality of task files into a plurality of sub-files, sending the sub-files to different medium-orbit satellites, and sending the sub-files to low-orbit satellites which do not receive the sub-files by the medium-orbit satellites; s2, the low earth orbit satellites receiving the subfiles determine the observed quantity of each neighbor low earth orbit satellite, and stack the observed quantity into an input matrix; s3, generating a weighted feature matrix of the input matrix by adopting a dendritic neural network and an attention mechanism module; s4, selecting neighbor low-orbit satellites in the weighted feature matrix, and sending the received subfiles to the selected neighbor low-orbit satellites in parallel; s5, judging whether the current time is a set time period or not, if yes, entering S6, and if not, entering S2 to continue execution by all the low-orbit satellites which receive the sub-files at present; and S6, judging whether all the target low-orbit satellites receive all the task files or not, if so, terminating the transmission decision method, and if not, entering the step S2 to continue execution by all the low-orbit satellites which receive the sub-files at present.

The application relates to an aptamer-membrane fusion liposome nanomedicine as well as a preparation method and application thereof, and belongs to the technical field of nanomedicine preparation. The aptamer-membrane fusion liposome nanomedicine disclosed by the application is formed based on the affinity between the cholesterol (Chol) at the 3' end of an aptamer and a liposome, has small bond energy, good spatial orientation, high selectivity and reversibility. In the aptamer-membrane fusion liposome nanomedicine, the liposome can be fused with a membrane, co-loaded auranofin (AUR) has the functions of promoting cell iron death and sensitizing radiotherapy, the immunoadjuvant aptCpG can target dendritic cells (DCs), stimulate the functions of DCs maturation and antigen presentation, and further activate subsequent immune responses. The bionic liposome nanomedicine provides a new way for improving the effectiveness of clinical malignant tumor treatment.

The present application relates to a kind of universal preparation method for presenting tumor antigen and highly activated T cell exosome, belong to biomedical and immunotherapy technical field.The present application described method is first synthesized the tumor antigen specificity nano stimulant capable of activating dendritic cell, makes dendritic cell carry IFN-β, expresses specific tumor-related antigen and costimulatory molecule, to solve the problems, such as low antigen presentation efficiency, T cell activation deficiency and high cost of individualized treatment in the existing tumor immunotherapy method.Exosome is extracted from the supernatant of the above dendritic cell culture.The preparation method of the present application not only significantly improves the efficiency of exosome as antigen presentation carrier, effectively and specifically stimulates T cell, but also reduces the preparation cost, provides more effective general solution for tumor immunotherapy, has wide application prospect and clinical value.

The purpose of the present invention is to provide a method for preparing a dendritic cell from a monocyte using a platelet lysate.　Provided is a method for preparing a dendritic cell having cytotoxicity from a monocyte, the method comprising culturing a monocyte separated from peripheral blood by non-adhesive culture using a serum-free culture medium containing a human platelet lysate (HPL), GM-CSF and PEG conjugated interferon-α, adding prostaglandin E2 and OK432 to the resultant culture, and further culturing the resultant mixture by non-adhesive culture.

The inventors have prepared a novel anti-Cath-D antibody (F1M1) that can reduce tumor growth in a Cath-D secreting basal-like TNBC cell line with strong immune infiltration, without significant toxicity. The F1M1 antibody prevents recruitment of immunosuppressive M2 polarized tumor-associated macrophages (TAMs) and induces activation of natural killer cells in the tumor, and the F1M1 also enhances activation of antitumor M1 polarized TAM, recruitment and maturation of conventional cDC1 dendritic cells in the tumor to promote antigen presentation and reduce depletion marker expression of CD4 + and CD8 + T cells in the tumor and drainage lymph nodes. It is worthy of noting that the affinity of the antibody F1M1 to Cath-D is better than that of the antibody F1 prepared by the inventor in advance. The inventors also have prepared a novel Fc-optimized F1M1-Fc + human antibody which can promote ADCC induction of cancer cells and CAF, improve anti-tumor efficacy, and trigger recruitment, activation and cytotoxic activity of NK cells in tumors. The F1M1-Fc + F1M1-Fc + can inhibit the growth of MDA-MB-231 and SUM159 TNBC cell xenografts and two TNBC-PDX (one of the TNBC-PDX is resistant to neoadjuvant chemotherapy), and has no obvious toxicity. In addition, the F1M1-Fc < + > improves the treatment effect of the paclitaxel and enzalutamide combined medicine. Thus, the present invention relates to anti-cathepsin-D antibodies and their use in the treatment of cancer, in particular triple negative breast cancer.

The application of the autologous dendritic cell in preparation of the medicine for treating the nerve injury erectile dysfunction can well promote recovery of the erectile function, perform staged reinfusion, induce immune regulation, repair nerve and blood vessel functions and improve a sex hormone regulation pathway. And the autologous dendritic cells are derived from a user, and have the advantages of safety, effectiveness and convenience in use. The combined immune cell therapy is obviously superior to a single treatment path in efficacy, is also more suitable for chronic, non-structural, subclinical and other ED people which are difficult to intervene by traditional methods, and has stronger individual adaptation ability and long-term controllability at the same time. Compared with a traditional scheme, the cell therapy targeting is better, and the treatment effect is faster.

Provided herein are methods for generating extracellular vesicles (EVs) from massively cultured polarized DCs, as well as additional operations of separating CTLA-4 + EV and CTLA-4-EV from each other and recovering the two EV populations in a physically and functionally intact state; also provided is a composition comprising the EV obtained by the method. In addition, the use of CTLA-4-EV in the treatment of cancer, as well as the use of CTLA-4 + EV in the treatment of GVHD and other T cell mediated autoimmune conditions, is also provided.